SYDNEY, AUSTRALIA–(Marketwired – May 6, 2016) – Simavita Limited (“Simavita” or the “Company“) (TSX VENTURE:SV)(ASX:SVA) today announced that, as foreshadowed in the changes to board and management announced on April 27, 2016, Craig Holland, Non-Executive Director and Chairman of the Audit & Risk Committee has resigned from the Board of Directors effective immediately.
The Company would like to thank Mr Holland for his contributions over the past 18 months particularly his contribution as the Chairman of the Audit & Risk Committee.
For further information, please check our website (www.simavita.com) or contact the persons outlined below.
About Simavita
Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.
About SIM™
SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect record and report incontinence events during a compulsory or recommended assessment period in residential aged care sites to develop an evidence-based incontinence care plan.
Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.
The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.
Ms Peta Jurd
+61 421 466 653
pjurd@simavita.com
Media and Investor Relations
Glen Zurcher
+61 420 249 299
glen.zurcher@irdepartment.com.au